Genematrix Begins Phase 1 Trial of Domestically Developed Hepatitis A Vaccine
Predicted impact: Medium
Phase 1 start for a hepatitis A vaccine; early-stage, small company with market value about 29.6 billion won.
109820 · KOSDAQ · ₩109820 · 진매트릭스
Predicted impact: Medium
Phase 1 start for a hepatitis A vaccine; early-stage, small company with market value about 29.6 billion won.
Also known as: Genematrix / 진매트릭스 / 109820 / KRX:109820
Source: KRX statistical information